


SARS-CoV-2 Total Assay¹

Secure your community with science and scale

A total antibody assay helps give a complete picture of infection status and immune response



S1RBD

Smart selection of S1RBD antigen looks to the future and protects today

The antibody test is highly accurate in identifying SARS-CoV-2 antibodies and is designed to detect the spike protein receptor binding domain (S1RBD) on the surface of the SARS-CoV-2 virus which binds the virus to cells via a distinct human receptor (ACE2) found in lungs, heart, multiple organs and blood vessels.

Evidence shows antibodies to the spike protein are **neutralizing** – an important link to vaccine development

SARS-CoV-2 spike protein

Human cell

ACE2 Receptor

SARS-CoV-2



AD VIA Centaur[®] Family



Atellica[®] Solution



Dimension[®] Family

Clinical reach with

~20,000

analyzers worldwide²

100% sensitivity³
& 99.8% specificity⁴

Up to 440
tests/hour⁵

1. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Product availability may vary by country and is subject to regulatory requirements.

2. Installed base of ADVIA Centaur XP, ADVIA Centaur XPT, ADVIA Centaur CP, Atellica Solution, Dimension Vista and Dimension EXL analyzers.

3. For samples collected ≥14 days after positive PCR result.

4. Based on results for the ADVIA Centaur COV2T assay.

5. Depending on test mix and configuration using Atellica Solution.

HOOD05162003093539